TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33564120
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) combined with standard chemotherapy
Study: 33564120
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy alone (control)
Study: 33367742
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Clomiphene Citrate (CC) from Day 3 to 7 and 450 IU HMG
Study: 33367742
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Clomiphene Citrate (CC) from Day 3 to 7 and 150 IU HMG
Study: 33367742
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Clomiphene Citrate (CC) and 450 IU HMG
Study: 33367742
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Clomiphene Citrate (CC) and 150 IU HMG
Study: 37745675
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (≤2 mg/kg daily) in SLS I
Study: 37745675
Drug: Oral mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mycophenolate mofetil (1500 mg twice daily) in SLS II
Study: 37745675
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (≤2 mg/kg daily) in SLS II
Study: 37745675
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment groups pooled from SLS I and SLS II
Study: 35051151
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (intraarticular O2-O3 mixture hip injections with ozonated autohemotherapy)
Study: 34700600
Drug: DWI-guided dose-painting
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWI-guided dose-painting radiotherapy (DP-RT)
Study: 32312010
Drug: HBO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO therapy (Group A)
Study: 32312010
Drug: No HBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: No HBO therapy (Group B)
Study: 34687214
Drug: Bimekizumab 320
Normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 320 mg at weeks 0/4, followed by bimekizumab 320 mg at week 16
Study: 34687214
Drug: Bimekizumab 320
Normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 320 mg at weeks 0/4, followed by placebo at week 16
Study: 33685888
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (2.4 mg/kg body weight i.v. artesunate at 0 and 12 h)
Study: 33685888
Drug: Simplified regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified regimen (4 mg/kg i.v. artesunate at 0 h)
Study: 34583525
Drug: Autologous mesenchymal
Normalized name: AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS
DrugBank: Debamestrocel (DB17934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous mesenchymal stem cell (MSC) treatment
Study: 33413233
Drug: Group-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based intervention consisting of 12 weekly sessions delivered in primary care settings and community assets.
Study: 33902493
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (8 sessions, 1 hour each) for parents or guardians
Study: 35908457
Drug: oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral conjugated equine estrogens (o‐CEE, n = 104)
Study: 35908457
Drug: transdermal 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal 17β‐estradiol (t‐E2, n = 119)
Study: 33758944
Drug: Strawberry consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry consumption (2 × 25 g freeze-dried strawberry powder twice daily for 4 weeks)
Study: 36433709
Drug: Janagliflozin 25
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Janagliflozin 25 mg
Study: 36433709
Drug: Janagliflozin 50
Normalized name: canagliflozin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Janagliflozin 50 mg
Study: 36433709
Drug: Janagliflozin 25
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Janagliflozin 25 mg and 50 mg
Study: 32171183
Drug: Compression garment
Normalized name: EXTREMIT-EASE Ready-To-Wear 30-50mmHg Compression Garment (Large)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression garment (CG) worn daily for 23 hours.
Study: 36232995
Drug: Citrate Dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate Dialysate (1 mmol/L)
Study: 36232995
Drug: Acetate Dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate Dialysate (4 mmol/L)
Study: 33113783
Drug: Control drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drug (10% ethanol)
Study: 35084634
Drug: Intralesional platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional platelet-rich plasma (PRP) injection
Study: 35950601
Drug: Generic (test)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic (test) edoxaban 60-mg tablet in fasting condition
Study: 35950601
Drug: Generic (test)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic (test) edoxaban 60-mg tablet in fed condition
Study: 35950601
Drug: Branded (reference)
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded (reference) edoxaban 60-mg tablet in fasting condition
Study: 35950601
Drug: Branded (reference)
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded (reference) edoxaban 60-mg tablet in fed condition
Study: 33563752
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with FGFR and MEK inhibitors
Study: 33563752
Drug: FGFR-specific inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGFR-specific inhibitors (BGJ398, erdafitinib, TAS-120)
Study: 32668456
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg albendazole
Study: 32641091
Drug: Chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine phosphate treatment for no more than 10 days
Study: 32641091
Drug: Lopinavir/ritonavir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir treatment for no more than 10 days
Study: 32641091
Drug: Chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine phosphate treatment
Study: 36155062
Drug: 0.5 g%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g% MSG in drinking water
Study: 36155062
Drug: 1.5 g%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g% MSG in drinking water
Study: 36155062
Drug: 3.0 g%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g% MSG in drinking water
Study: 36155062
Drug: 3.0 g%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g% MSG in drinking water (withdrawn after 4 weeks)
Study: 32972483
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy for psychosis (CBTp) using a novel tabletised manual
Study: 35585570
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of conbercept (IVC) 3 days before PPV
Study: 35585570
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of conbercept (IVC) after PPV
Study: 33128790
Drug: COPE‐TeL programme
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPE‐TeL programme (12-week intervention including comprehensive oral and physical exercises and textured lunch gatherings)
Study: 34267185
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose vaccine
Study: 34267185
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vaccine
Study: 33024237
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 mg/day)
Study: 35100493
Drug: LC hair
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC hair essence serum injection (1 ml diluted with 0.5 ml of 0.9% normal saline, once weekly for 8 weeks)
Study: 35100493
Drug: Botulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin-A injection (50 units)
Study: 36042439
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (PN) commenced on day 1 or day 2 of admission
Study: 36042439
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (PN) commenced on day 6 of admission
Study: 33960081
Drug: Saffron 100
Normalized name: SAFFRON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron 100 mg/day for 8 weeks
Study: 33481863
Drug: Postpartum mothers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum mothers with family monthly income <150 USD
Study: 32948138
Drug: Lower Criteria
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower Criteria Group (fasting plasma glucose < 5.1 mmol/L, AND 1 hour < 10.0 mmol/L, AND 2 hour < 8.5 mmol/L)
Study: 32948138
Drug: Higher Criteria
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher Criteria Group (fasting plasma glucose < 5.5 mmol/L, AND 2 hour < 9.0 mmol/L)
Study: 35045272
Drug: Clinical expertise
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical expertise in critical care or pulmonary medicine
Study: 39612012
Drug: Home parenteral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home parenteral nutrition (HPN)
Study: 34355250
Drug: ABP 980
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABP 980 (6 mg/kg) plus pertuzumab (420 mg)
Study: 34355250
Drug: Trastuzumab RP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab RP (6 mg/kg) plus pertuzumab (420 mg)
Study: 35306390
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA treatment with BDI-II scores ≥ 18 at baseline
Study: 35306390
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA treatment with BDI-II scores < 18 at baseline
Study: 32487263
Drug: Best practices
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practices for rational use of antibiotics (Control)
Study: 35044504
Drug: High-dose Lycium
Normalized name: Berberis lycium whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Lycium barbarum (20 g, containing 20 mg of zeaxanthin and 2 mg of lutein)
Study: 35044504
Drug: Low-dose Lycium
Normalized name: Berberis lycium whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose Lycium barbarum (10 g, containing 10 mg of zeaxanthin and 1 mg of lutein)
Study: 35044504
Drug: Low-dose control
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose control (1 mg of lutein)
Study: 35044504
Drug: High-dose control
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose control (2 mg of lutein)
Study: 32202814
Drug: Supportive‐expressive (SE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive‐expressive (SE) psychodynamic treatment
Study: 35062752
Drug: Standard three-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard three-dose (SD) Hepatitis B vaccine
Study: 35062752
Drug: Double three-dose
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double three-dose (DD) Hepatitis B vaccine
Study: 34882644
Drug: Biologics treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics treatment
Study: 34331755
Drug: Kaltenborn-Evjenth orthopedic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaltenborn-Evjenth orthopedic manual therapy (KEOMT)
Study: 35238704
Drug: Standard del
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard del Nido cardioplegia solution (SDN)
Study: 35238704
Drug: Modified del
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified del Nido cardioplegia solution (MDN)
Study: 32433753
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 2g temocillin
Study: 32433753
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of 2g temocillin
Study: 32090996
Drug: 3D laser
Normalized name: aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D laser scanner (3DLS) and tablet computer for digitally assisted BCRL assessment
Study: 34566523
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day plus rosuvastatin 20 mg/day (combination group)
Study: 34566523
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg/day (rosuvastatin group)
Study: 35753872
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (active)
Study: 34310400
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg V-01 (two-dose regimen)
Study: 34310400
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg V-01 (two-dose regimen)
Study: 34310400
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg V-01 (one-dose regimen)
Study: 34310400
Drug: Placebo (two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two-dose regimen)
Study: 34310400
Drug: Placebo (one-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one-dose regimen)
Study: 32769506
Drug: Fluid intake
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid intake group (allowed to drink up to 400 ml of apple juice for 90 minutes after randomisation)
Study: 32660769
Drug: Reference Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reference Pegfilgrastim (Neulasta) (6 mg/0.6 mL)
Study: 34498320
Drug: Adapted soccer
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted soccer programme (twice a week for 16 weeks)
Study: 34498320
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual daily regime)
Study: 33962594
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: One additional dose of 1g IV‐TXA 3 hours postoperatively
Study: 33962594
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Three doses of 1g IV‐TXA at 3, 6, and 12 hours postoperatively
Study: 36910518
Drug: Early discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early discontinuation of dual antiplatelet therapy (DAPT)
Study: 36067589
Drug: 28 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 g/d of dry roasted, unsalted peanuts for 6 weeks
Study: 33829580
Drug: Anti-PD-1/PD-L1 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, or atezolizumab)
Study: 32878758
Drug: Preoperative endoscopic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative endoscopic injection of botulinum toxin (BTX) into the sphincter of Oddi
Study: 34820909
Drug: 550 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg/d supplemental choline (as choline chloride)
Study: 34820909
Drug: 25 mg/d
Normalized name: fluoride 0.25 mg/drop oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/d d9-choline (control)
Study: 34630560
Drug: Associated Mirror
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Associated Mirror Therapy (AMT)
Study: 32461554
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg twice-daily for 3 months
Study: 33090614
Drug: Resistance to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance to amoxicillin
Study: 34147151
Drug: Upadacitinib in
Normalized name: Product containing upadacitinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib in combination with topical corticosteroids
Study: 33560659
Drug: Ketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.25 mg·kg‐1 bolus followed by 5 µg·kg‐1·min‐1 infusion for up to 45 minutes)
Study: 32848185
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron supplementation (800 mg iron-carboxymaltose)
Study: 33337237
Drug: P. foliicola
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. foliicola spore suspension (1.0 × 10^6/ml) applied to three-week-old seedlings of mung bean cultivar 'Jilv 7' (n=5)
Study: 33236939
Drug: Transcatheter mitral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter mitral valve repair (TMVr) plus guideline directed medical therapy (GDMT)
Study: 33236939
Drug: Guideline directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline directed medical therapy (GDMT) alone
Study: 39773831
Drug: Rivaroxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (15 mg once daily)
Study: 35292423
Drug: Rivaroxaban and
Normalized name: rivaroxaban and acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban and Aspirin (both groups)
Study: 35674919
Drug: Prenatal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal morphine treatment (twice daily, s.c. from gestational days 11–18)
Study: 32125709
Drug: optimal standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: optimal standard therapy (control group)
Study: 34269426
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER 100 mg
Study: 34269426
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER 200 mg
Study: 34269426
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER 400 mg
Study: 34269426
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER 200 mg (adolescents)
Study: 34269426
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER 400 mg (adolescents)
Study: 34269426
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER 600 mg (adolescents)
Study: 34269426
Drug: Missed doses
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Missed doses of viloxazine ER
Study: 32448254
Drug: High treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High treatment expectations at baseline
Study: 35511322
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor physical therapy including electromyographic biofeedback for 8 weeks
Study: 34246277
Drug: Inpatient statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient statin use (Atorvastatin was the most commonly prescribed, n = 205, 82%)
Study: 34813125
Drug: HTK-N solution
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTK-N solution
Study: 35906457
Drug: Daily sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sleep quality
Study: 37016357
Drug: Daily sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sleep duration
Study: 35298282
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) treatment, 2 treatments spaced 3 weeks apart
Study: 35298282
Drug: Heated Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated Eye Mask (HEM), daily for 6 weeks (42 days)
Study: 35298282
Drug: Both IPL
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IPL and HEM treatments
Study: 34455106
Drug: 35% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% hydrogen peroxide gel with violet LED (3 sessions of 15 min each, with 7 days interval)
Study: 34455106
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change of the bleaching gel during each session (NBGR)
Study: 34455106
Drug: 3 changes
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 changes of the bleaching gel every 5 min for each session (BGR)
Study: 32706534
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D group (14,000 IU of vitamin D3 weekly for 3 years)
Study: 34275632
Drug: Moderate milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate milk level (MM) treatment
Study: 34275632
Drug: Lower milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower milk level (LM) treatment